<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688021</url>
  </required_header>
  <id_info>
    <org_study_id>TZ-001</org_study_id>
    <nct_id>NCT04688021</nct_id>
  </id_info>
  <brief_title>A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.</brief_title>
  <official_title>A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yi Luo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll haploidentical HSCT patients with high risk for acute GVHD.&#xD;
      Tocilizumab (8mg/kg) will be added to the conventional acute GVHD prophylaxis regime&#xD;
      (CsA+Methotrexate(MTX)+low dose mycophenolate mofetil(MMF)+ATG) on day -1 of transplant. The&#xD;
      previous patients will be used as control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of grade II-IV acute graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
    <description>Date of symptom onset, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of grade II-IV acute graft-versus-host disease (aGVHD) will be recorded. The aGVHD score of each affected organ will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of non grade II-IV acute graft-versus-host disease survival</measure>
    <time_frame>100 days</time_frame>
    <description>All patients will be tracked from Day 0 to date of grade II-IV acute graft-versus-host disease (aGVHD) onset. Patients who did not present grade II-IV aGVHD or died will be censored at the last date they were assessed and deemed free of grade II-IV aGVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of engraftment</measure>
    <time_frame>100 days</time_frame>
    <description>All patients will be tracked from Day 0 to date of myeloid and platelet engraftments, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of infections</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of infection diagnosis as proved by relevant standard diagnostic criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant-related nonrelapse mortality (NRM)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of disease relapse or progression</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Leukemia</condition>
  <condition>Graft-versus-host-disease</condition>
  <arm_group>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>4 mg/m2/day administered IV day -10 through -9.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3.2 mg/kg/day administered IV day -8 through -6.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1.8 g/m2/day administered IV day -5 through -4.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Me-CCNU</intervention_name>
    <description>250mg/m2 once administered orally on day -3.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit antithymocyte globulin</intervention_name>
    <description>1.5mg/kg/day administered IV day -5 through -2.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>8mg/kg administered IV on day -1.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic HSCT</intervention_name>
    <description>Day 0</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.</description>
    <arm_group_label>Tocilizumab cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematological malignancies in complete remission (CR) who are eligible&#xD;
             and planned for haploidentical HSCT. The donor specific antibody is negative&#xD;
&#xD;
          -  Patient age 16-60 years&#xD;
&#xD;
          -  Mother donor, or female donor (age &gt;50) for female-male transplant&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2&#xD;
&#xD;
          -  Creatinine clearance rate &gt; 60 mL/min (estimate by Cockcroft-Gault Equation)&#xD;
&#xD;
          -  alanine transaminase (ALT) and aspartate aminotransferase (AST)≤ 2.5×upper limit of&#xD;
             normal (ULN), and total bilirubin ≤ 1.5×ULN （upper limit of normal, ULN）&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50% as measured by echocardiography&#xD;
&#xD;
          -  Acceptation to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous HSCT&#xD;
&#xD;
          -  Present active infection (including bacterial, virus or fungal)&#xD;
&#xD;
          -  History of Tocilizumab infection&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  History of demyelinating disease&#xD;
&#xD;
          -  Patients who are HIV-positive, or with uncontrolled chronic hepatitis B virus (HBsAg&#xD;
             positive) or hepatitis C virus (anti-HCV) infections&#xD;
&#xD;
          -  Women who are pregnant (β-chorionic gonadotropin+) or breast feeding&#xD;
&#xD;
          -  Refusal to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Luo, MD</last_name>
    <phone>86-13666609126</phone>
    <email>luoyijr@zju.edu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lizhen Liu, MD</last_name>
    <phone>86-15858222740</phone>
    <email>lizhenliuzju@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Luo, MD</last_name>
      <phone>86-13666609126</phone>
      <email>luoyijr@zju.edu.com</email>
    </contact>
    <contact_backup>
      <last_name>Lizhen Liu, MD</last_name>
      <phone>86-15858222740</phone>
      <email>lizhenliuzju@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>graft-versus-host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

